This inventor holds 2 USPTO granted patents. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- La Jolla, CA (US) (2013)
- San Diego, CA (US) (2013)
Company Filing History:
2 out of 164 
2 out of 40 
Years Active: 2013
Title: Dennis Kim: Innovator in Metabolic Disease Treatments
Introduction
Dennis Kim is a notable inventor based in La Jolla, CA (US). He has made significant contributions to the field of metabolic diseases, particularly through his innovative patents. With a total of 2 patents, Kim's work focuses on improving health outcomes related to cardiovascular risks and liver diseases.
Latest Patents
One of Dennis Kim's latest patents involves the use of exendins and GLP-1 receptor agonists for altering the concentration of fibrinogen. This invention aims to decrease fibrinogen concentration, which can improve the cardiovascular risk profile of a subject. Another significant patent addresses the use of Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. This invention explores the novel use of incretin compounds and amylinomimetic compounds to treat various metabolic conditions.
Career Highlights
Throughout his career, Dennis Kim has worked with prominent companies in the pharmaceutical industry. He has been associated with Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. His experience in these organizations has contributed to his expertise in developing innovative treatments for metabolic diseases.
Collaborations
Dennis Kim has collaborated with several professionals in his field, including Alain D. Baron and Matthew Wintle. These collaborations have likely enhanced his research and development efforts.
Conclusion
Dennis Kim's contributions to the field of metabolic disease treatments through his patents demonstrate his commitment to improving health outcomes. His innovative approaches continue to influence the medical community and offer hope for better management of metabolic conditions.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile